Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
Public ClinicalTrials.gov record NCT01993810. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This randomized phase III trial studies proton chemoradiotherapy to see how well it works compared to photon chemoradiotherapy in treating patients with stage II-IIIB non-small cell lung cancer that cannot be removed by surgery. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor, such as photon or proton beam radiation therapy, may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as paclitaxel, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether proton chemoradiotherapy is more effective than photon chemoradiotherapy in treating non-small cell lung cancer.
Study identification
- NCT ID
- NCT01993810
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 330 participants
Conditions and interventions
Conditions
Interventions
- Carboplatin Drug
- Cisplatin Drug
- Durvalumab Biological
- Etoposide Drug
- Paclitaxel Drug
- Pemetrexed Disodium Drug
- Photon Beam Radiation Therapy Radiation
- Proton Beam Radiation Therapy Radiation
- Quality-of-Life Assessment Other
- Questionnaire Administration Other
Drug · Biological · Radiation + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2, 2014
- Primary completion
- Nov 29, 2028
- Completion
- Nov 29, 2028
- Last update posted
- Jun 7, 2026
2014 – 2028
United States locations
- U.S. sites
- 30
- U.S. states
- 12
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Florida Health Science Center - Jacksonville | Jacksonville | Florida | 32209 | — |
| Northwestern Medicine Cancer Center Warrenville | Warrenville | Illinois | 60555 | — |
| Maryland Proton Treatment Center | Baltimore | Maryland | 21201 | — |
| University of Maryland/Greenebaum Cancer Center | Baltimore | Maryland | 21201 | — |
| Upper Chesapeake Medical Center | Bel Air | Maryland | 21014 | — |
| Central Maryland Radiation Oncology in Howard County | Columbia | Maryland | 21044 | — |
| Tate Cancer Center | Glen Burnie | Maryland | 21061 | — |
| Massachusetts General Hospital Cancer Center | Boston | Massachusetts | 02114 | — |
| Mass General/North Shore Cancer Center | Danvers | Massachusetts | 01923 | — |
| Siteman Cancer Center at West County Hospital | Creve Coeur | Missouri | 63141 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey | 07920 | — |
| ProCure Proton Therapy Center-Somerset | Somerset | New Jersey | 08873 | — |
| Memorial Sloan Kettering Commack | Commack | New York | 11725 | — |
| Memorial Sloan Kettering Westchester | Harrison | New York | 10604 | — |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | — |
| Memorial Sloan Kettering Rockville Centre | Rockville Centre | New York | 11570 | — |
| Memorial Sloan Kettering Sleepy Hollow | Sleepy Hollow | New York | 10591 | — |
| University of Cincinnati Medical Center | Cincinnati | Ohio | 45267 | — |
| West Chester Hospital | West Chester | Ohio | 45069 | — |
| University of Pennsylvania/Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | — |
| Thomas Jefferson University Hospital | Philadelphia | Pennsylvania | 19107 | — |
| Tennessee Cancer Specialists-Dowell Springs | Knoxville | Tennessee | 37909 | — |
| M D Anderson Cancer Center | Houston | Texas | 77030 | — |
| MD Anderson Regional Care Center-Katy | Houston | Texas | 77094 | — |
| MD Anderson Regional Care Center-Bay Area | Nassau Bay | Texas | 77058 | — |
| MD Anderson Regional Care Center-Sugar Land | Sugar Land | Texas | 77478 | — |
| MD Anderson Regional Care Center-The Woodlands | The Woodlands | Texas | 77384 | — |
| ProCure Proton Therapy Center-Seattle | Seattle | Washington | 98133 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01993810, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 7, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01993810 live on ClinicalTrials.gov.